The exon 19-deleted EGFR undergoes ubiquitylation-mediated endocytic degradation via dynamin activity-dependent and -independent mechanisms

Reticulon 3–dependent ER-PM contact sites control EGFR nonclathrin endocytosis

(2017) Giusi Caldieri et al.   SCIENCE

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells

(2016) Yingqiu Zhang et al.   CANCER LETTERS

Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs

(2016) Wolfgang Brückl et al.   Expert Review of Anticancer Therapy

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016

(2016) Daniel S.W. Tan et al.   Journal of Thoracic Oncology

Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

(2015)   LANCET

Quantitative analysis reveals how EGFR activation and downregulation are coupled in normal but not in cancer cells

(2015) Fabrizio Capuani et al.   Nature Communications

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors

(2014) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Threshold-controlled ubiquitination of the EGFR directs receptor fate

(2013) Sara Sigismund et al.   EMBO JOURNAL

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

Governance of Endocytic Trafficking and Signaling by Reversible Ubiquitylation

(2012) Michael J. Clague et al.   DEVELOPMENTAL CELL

Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: Therapeutic implications

(2011) M. Sánchez-Martín et al.   INTERNATIONAL JOURNAL OF CANCER

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy

(2010) Gur Pines et al.   FEBS LETTERS

Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer

(2009) Tetsuya Mitsudomi et al.   FEBS Journal

Endocytosis and signalling: intertwining molecular networks

(2009) Alexander Sorkin et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel

(2008) A. Sawai et al.   CANCER RESEARCH

Clathrin-Mediated Internalization Is Essential for Sustained EGFR Signaling but Dispensable for Degradation

(2008) Sara Sigismund et al.   DEVELOPMENTAL CELL

Endocytosis and intracellular trafficking of ErbBs

(2008) Alexander Sorkin et al.   EXPERIMENTAL CELL RESEARCH